Biosenta Inc.
ZRO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -48,800.00% | 146,200.00% | 0.00% | -50.00% | 50.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -48,800.00% | 146,200.00% | 0.00% | -50.00% | 50.00% |
| Cost of Revenue | 0.00% | -96.15% | 0.00% | 0.00% | -99.15% |
| Gross Profit | -146,300.00% | 5,952.00% | -- | 0.00% | 100.43% |
| SG&A Expenses | -23.53% | -24.59% | -49.26% | 0.28% | 36.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.82% | -23.46% | -45.16% | -0.55% | 21.28% |
| Operating Income | -19.00% | 63.33% | 45.22% | 0.49% | -21.26% |
| Income Before Tax | 86.56% | -8.67% | -47.47% | -94.33% | -434.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.56% | -8.67% | -47.47% | -94.33% | -434.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.56% | -8.67% | -47.47% | -94.33% | -434.02% |
| EBIT | -19.00% | 63.33% | 45.22% | 0.49% | -21.26% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 85.09% | 13.13% | -24.07% | -70.13% | -252.78% |
| Normalized Basic EPS | -77.59% | 13.00% | -23.53% | -70.83% | 39.58% |
| EPS Diluted | 85.09% | 13.13% | -24.07% | -70.13% | -252.78% |
| Normalized Diluted EPS | -77.59% | 13.00% | -23.53% | -70.83% | 39.58% |
| Average Basic Shares Outstanding | -9.94% | 24.82% | 19.44% | 15.02% | 118.66% |
| Average Diluted Shares Outstanding | -9.94% | 24.82% | 19.44% | 15.02% | 118.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
